EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

NCT01012102 | Completed Phase 1

• 1 other identifier: EMR 200032-001
• Study Type: interventional
• Target: 104
• Locations: 0 countries
• Sites: N/A

Brief Summary

To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy. The primary target variable is the immune response as assessed by ELISPOT before and until week 17 after vaccination with EMD 640744 in Montanide® ISA 51 VG.

Conditions

Advanced Solid Tumors

Keywords

EMD 640744; Montanide; Advanced solid tumours

Outcome Measures

Primary Outcomes (1)

• To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy

  1-4 weeks

Secondary Outcomes (2)

• To assess the safety and tolerability of different doses of EMD 640744 in Montanide® ISA 51 VG in terms of laboratory parameters and adverse event profile.

  3 months

• To assess the clinical efficacy in terms of the overall response, progression-free survival time, and survival time.

  3 months

Study Arms (3)

Group 1

EXPERIMENTAL

EMD 640744 30μg and Montanide® ISA 51 VG

Biological: EMD 640744; Other: Montanide ISA 51 VG

Group 2

EXPERIMENTAL

EMD 640744 100μg and Montanide® ISA 51 VG

Biological: EMD 640744; Other: Montanide ISA 51 VG

Group 3

EXPERIMENTAL

EMD 640744 300μg and Montanide® ISA 51 VG

Biological: EMD 640744; Other: Montanide ISA 51 VG

Interventions

EMD 640744 BIOLOGICAL

EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)

Group 1

Montanide ISA 51 VG OTHER

Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)

Group 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects ≥18 years of age
• Signed written informed consent
• Histologically or cytologically documented metastatic or locally advanced survivin-expressing solid tumor for which no established therapy exists
• Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic, or laboratory criteria established for the given tumor entity
• Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7 assessed by HLAgenotyping
• ECOG performance status of ≤1, estimated life expectancy of at least 3 months
• Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x 10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L
• Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN
• Adequate renal function defined by a serum creatinine ≤2 x ULN
• Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)
• Effective contraception for female and male subjects if the risk of conception exists

You may not qualify if:

• Treatment in another clinical study within the past 30 days prior to the first administration of study treatment
• Previous treatment with an investigational anticancer vaccine
• Requirement of concurrent treatment with a nonpermitted drug
• Active significant autoimmune disease (with the exception of vitiligo)
• Receipt of allogeneic stem cell transplantation
• Significant acute or chronic infections (e.g. viral hepatitis, HIV)
• Primary brain tumors and brain metastases (with the exception of brain metastases that are stable after irradiation or surgically resected brain metastases if subjects have been asymptomatic for ≥6 months)
• Rapidly progressive disease (e.g. tumor lysis syndrome)
• Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy or any investigational drug within 30 days before the start of study treatment
• Pregnancy or lactation
• Active drug or alcohol abuse
• Known hypersensitivity to the study treatment or any of its components
• Any significant disease that, in the Investigator's opinion, should exclude the subject from the study; for questions about this criterion, the Investigator should contact the sponsor.
• Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common Terminology Criteria For Adverse Events version 3.0
• Legal incapacity or limited legal capacity

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead

Related Publications (1)

• Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2.

  PMID: 24487961 RESULT

MeSH Terms

Interventions

montanide ISA 51

Study Officials

• Jens-Peter Marschner, MD

  Merck KGaA, Darmstadt

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 20, 2009
• First Posted: November 11, 2009
• Study Start: April 1, 2008
• Primary Completion: October 1, 2009
• Study Completion: September 1, 2011
• Last Updated: February 20, 2014

Record last verified: 2011-10